Genome variation and its affect on ACT treatment outcome in Tanzania
This study aims to assess the diversity of Plasmodium falciparum in regions of varying endemicity in Tanzania, and to investigate parasite genetic factors which might affect antimalarial treatment outcome among patients treated with ACTs. As part of the Plasmodium Diversity Network Africa (PDNA), an additional aim of this work is to build and strengthen the capacity of African investigators to conduct clinical trials and genomic studies in their local contexts. Over 400 samples were collected at three sites in Muheza and Muleba (hypoendemic), and Nachingwea (hyper-endemic/holoendemic) districts. The findings will provide baseline data and build the capacity for tracking and detection of emergence of artemisinin resistance in Tanzania. The PDNA is an African-led network investigating the genetic diversity and drug resistance of Plasmodium parasites across Africa.
Summary
- 300 Samples
- 3 Locations
- 2 Publications
Samples/Year
QC Pass
Samples that passed Whole-Genome Sequencing Quality Control (QC)
Resistance
Predicted resistance status for main antimalarial drug treatments from molecular markers
Locations
Kagera
Summary
Samples/Year
QC Pass
Samples that passed Whole-Genome Sequencing Quality Control (QC)
Resistance
Predicted resistance status for main antimalarial drug treatments from molecular markers
Lindi
Summary
Samples/Year
QC Pass
Samples that passed Whole-Genome Sequencing Quality Control (QC)
Resistance
Predicted resistance status for main antimalarial drug treatments from molecular markers
Tanga
Summary
Samples/Year
QC Pass
Samples that passed Whole-Genome Sequencing Quality Control (QC)
Resistance
Predicted resistance status for main antimalarial drug treatments from molecular markers